

**Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite # 380
Oak Park, CA 91377**

NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659

Register Online: www.heartindiabetes.com/registration

CME Symposium IN ASSOCIATION WITH THE 9th



EARN
CME
ABIM-MOC
CREDITS
1.75

CKD and Resistant HTN The Evolving Epidemic

Friday, June 6, 2025
7:00 pm – 9:00 pm EST
Loews Philadelphia Hotel
Philadelphia, PA

DINNER WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**

Free for all 9th HiD Attendees. Register online www.heartindiabetes.com/registration

Jointly Provided By: **MEEF**
FOUNDATION

CME MOC
ACCREDITED

CME solutions
EXPERT SOLUTIONS

Administered By: **TMIOA**



CKD AND RESISTANT HTN - THE EVOLVING EPIDEMIC

CHAIRS: **Yehuda Handelsman, MD • Matthew R. Weir, MD**

7:15 pm – 9:00 pm	DINNER CME SYMPOSIUM:	Supported by AstraZeneca
7:15 pm	Introduction & Pre-CME Questions	Matthew R. Weir, MD
7:30 pm	The Epidemiology and Pathophysiology of Resistant HTN and CKD	Matthew R. Weir, MD
7:50 pm	Management of CKD with/without Albuminuria	Christian W. Mende, MD
8:10 pm	Emerging Approaches to the Treatment of Resistant HTN	Raymond R. Townsend, MD
8:30 pm	Panel Discussion and Q&A: Case Presentation – Treatment Resistant HTN Panel: Christian W. Mende, MD, Raymond R. Townsend, MD, Matthew R. Weir, MD Moderator: Yehuda Handelsman, MD	
8:55 pm	Post-CME Questions & Concluding Remarks	
9:00 pm	Adjourn	

Program Description

Resistant hypertension is often a sign of poor treatment adherence, but it can also be caused by hyperaldosteronism, in which excess levels of aldosterone may lead to increases in blood pressure and consequently increased risk of HF, stroke, myocardial infarction, and other ASCVD events. Understanding the connections between hypertension, resistant hypertension, and CKD is vital for clinicians who manage patients with CRM conditions. This satellite symposium will address the challenges of optimal management of resistant hypertension and CKD.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Describe the epidemiologic and pathophysiology of hypertension, resistant hypertension, and CKD
- Compare and contrast therapies available for the management of CKD in people with and without albuminuria and with and without diabetes
- Review the management of hypertension and resistant hypertension and describe available and emerging therapeutic agents for resistant hypertension
- Develop strategies to address the needs of patients with treatment-resistant hypertension

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

FACULTY



Yehuda Handelsman, MD, Chair
FACP, FNLA, FASPC, FAHA, MACE
Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory Board
DCMI- Diabetes CardioRenal & Metabolism Institute
Chair & Program Director 9th HiD
Tarzana, California



Christian W. Mende, MD
FACP, FACN, FASN, FAHA
Clinical Professor of Medicine
University of California San Diego
Associate Editor of The Journal Diabetes
San Diego, California



Matthew R. Weir, MD, Chair
Professor and Chief, Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland



Raymond R. Townsend, MD, FAHA
Professor of Medicine
Associate Director
The Clinical and Translational Research Center
University of Pennsylvania
Philadelphia, Pennsylvania

CME DINNER SYMPOSIUM

This CME Supported Symposium is FREE for 9th HiD attendees and will stay on demand for ONE year following the meeting

Learn more at www.heartindiabetes.com/cmесymposium

To register to the entire Heart in Diabetes meeting
please visit www.heartindiabetes.com/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Solutions LLC, and Metabolic Endocrine Education Foundation (MEEF). CME Solutions LLC, is accredited by the ACCME to provide continuing medical education for physicians. Administred by the Metabolic Institute of America

CME Solutions LLC designated this live educational activity
for a maximum of 1.75 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent
of their participation in the activity.

For more information, please contact: info@tmioa.com or 818.342.1889

This is a CME program Supported by an Educational Grant from **AstraZeneca**